Rialto Wealth Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$303 Buy
15
+5
+50% +$134 ﹤0.01% 1844
2026
Q2
$253 Buy
10
+2
+25% +$44 ﹤0.01% 1832
2026
Q1
$179 Sell
8
-4
-33% -$96 ﹤0.01% 1616
2025
Q4
$321 Buy
12
+5
+71% +$119 ﹤0.01% 1412
2025
Q3
$150 Buy
7
+5
+250% +$118 ﹤0.01% 1545
2025
Q2
$44 Buy
+2
New +$37 ﹤0.01% 1647

Other funds holding ACAD

Rialto Wealth Management's ACAD Position: Q3 2026 in Review

Rialto Wealth Management increased its Acadia Pharmaceuticals (ACAD) stake by 50% in Q3 2026, buying an estimated $134 and bringing the position to 15 shares worth $303. The position accounts for ﹤0.01% of the portfolio, ranked #1844.

Rialto Wealth Management first reported a position in ACAD in Q2 2025 and has held it in 6 quarters since. The position peaked at $321 in Q4 2025. 351 funds tracked by Wall St. Rank hold ACAD as of Q3 2026.

  • Rialto Wealth Management held 15 shares of Acadia Pharmaceuticals worth $303 as of Q3 2026.
  • Rialto Wealth Management bought 5 Acadia Pharmaceuticals shares in Q3 2026, an estimated $134.
  • Acadia Pharmaceuticals made up ﹤0.01% of Rialto Wealth Management's portfolio in Q3 2026, its #1844 holding.
  • Rialto Wealth Management first reported a position in Acadia Pharmaceuticals in Q2 2025 and has held it in 6 quarters since.
  • Rialto Wealth Management's Acadia Pharmaceuticals position peaked at $321 in Q4 2025.
  • 351 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2026.

Based on Rialto Wealth Management's 13F filing for Q3 2026, filed 16 Nov 2026.